logo
AITX's RAD Dominates ISC West with Major Awards and Surge in Enterprise Leads

AITX's RAD Dominates ISC West with Major Awards and Surge in Enterprise Leads

RAD Secures Over 300 Qualified Leads at ISC West 2025
Detroit, Michigan--(Newsfile Corp. - April 7, 2025) - Robotic Assistance Devices, Inc. (RAD), a subsidiary of Artificial Intelligence Technology Solutions, Inc. (OTC Pink: AITX) (the 'Company'), achieved a major milestone at ISC West 2025, the premier event for security professionals. RAD earned both the Best in Threat Detection and Response Solutions award and the prestigious Judges' Choice Award at the SIA New Product Showcase, with its SARA ™ (Speaking Autonomous Responsive Agent) recognized as the standout innovation of the entire show.
Steve Reinharz, CEO/CTO of AITX and RAD, holds the SIA Judges' Choice Award earned by SARA, the AI Security Agent, during ISC West 2025, presented in the SARA Experience Zone at the RAD booth.
To view an enhanced version of this graphic, please visit:
These accolades reflect RAD's continued leadership in redefining physical security through artificial intelligence, robotics, and automation.
Beyond the awards, RAD connected with over 300 new prospects at the event, each verified and requesting follow-up. Nearly 50 of these prospects represent Fortune 1000 organizations, including six Fortune 50 companies not currently doing business with RAD. The volume and caliber of interest signal a rapid expansion of RAD's visibility and appeal across enterprise and institutional markets.
Widespread Industry Engagement
RAD's powerful lineup of solutions, including ROAMEO ™, RIO ™, AVA ™, SARA, ROSA ™, and its Firearm Detection analytic, sparked compelling conversations across numerous sectors:
Enterprise & Corporate Facilities: Multiple global organizations expressed strong interest in RAD's ability to automate perimeter patrols, improve visitor access control, and streamline monitoring operations through AI-driven systems.
Government & Scientific Institutions: Organizations overseeing critical infrastructure and space operations identified RAD's autonomous units as effective tools for safeguarding high-value assets and enhancing situational awareness.
Healthcare Networks: Several leading healthcare systems prioritized RAD's solutions for securing hospital exteriors and parking areas, with urgent deployment requests for ROAMEO, RIO and RAD Light My Way ™.
Logistics & Transportation: Major providers initiated RFP discussions focused on modernizing entry and exit operations, aiming to reduce reliance on manned guard stations by deploying RAD's integrated platforms.
Retail & Commercial Properties: Large retail chains outlined plans to replace parking lot guards with autonomous patrol units, citing RAD's effectiveness in enhancing deterrence and improving overall safety.
Aerospace & Defense: Operators of secure facilities and industrial campuses evaluated ROAMEO and RIO for deployment in perimeter and parking zone protection, recognizing the value of autonomous coverage in high-security environments.
Entertainment & Venues: Event venues and stadiums prioritized rapid integration of RAD solutions, including Security Operations Center (SOC) enhancements with SARA and active on-site deterrence using RIO and ROAMEO.
Market Trends Confirm RAD's Direction
Conversations throughout the event reinforced RAD's position at the forefront of security innovation, with recurring themes including:
Guard Force Reduction: Organizations are actively shifting toward automation to reduce dependency on traditional guard services and improve operational efficiency.
Parking & Perimeter Safety: Interest in ROAMEO and RIO continues to grow as organizations look to secure expansive, high-risk areas with solutions that offer consistent coverage and active deterrence.
AI-Driven Security Monitoring: Organizations are increasingly prioritizing real-time analytics and proactive, intelligent alerting as essential components of modern security strategies.
'Winning both our category and the overall Judges' Choice Award at ISC West is an extraordinary honor,' said Steve Reinharz, CEO/CTO of AITX and RAD. 'But what excites us even more is the overwhelming response from top-tier companies and institutions that see RAD as the future of security and automation.'
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the nearly $50 billion (US) security and guarding services industry i through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers these tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-R, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit www.aitx.ai, www.radsecurity.com, www.stevereinharz.com, www.radgroup.ai, www.raddog.ai, and www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the 'Company'). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
Steve Reinharz
949-636-7060

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Meryllion Resources Announces Related Party Loan
Meryllion Resources Announces Related Party Loan

Yahoo

time24 minutes ago

  • Yahoo

Meryllion Resources Announces Related Party Loan

Vancouver, British Columbia--(Newsfile Corp. - June 10, 2025) - Meryllion Resources Corporation (CSE: MYR) ("Meryllion" or the "Company") wishes to announce that it has entered into a loan agreement providing for a loan in the aggregate principal amount of CAD$195,000 (the "Loan") from Mr. David Steinepreis, a director of the Company. The Loan (i) is unsecured; (ii) has a term of 12 months; and (iii) bears interest at the rate of 6% per annum (said interest to be payable on a quarterly basis). The Company may prepay the Loan at any time, or from time to time, without penalty. The proceeds of the Loan will be used to pay certain accrued liabilities and for working capital purposes. The Loan is a related party transaction pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). With respect to the Loan, the Company has relied on the exemption from the valuation requirement pursuant to Section 5.5(b) (issuer not listed on specified markets) of MI 61-101 and from the minority shareholder approval requirement prescribed by Section 5.7(1)(a) (fair market value not more than 25% of market capitalization) of MI 61-101. For further information, please contact: Mr. Richard RevelinsDirector and Chief Executive OfficerMeryllion Resources Corporation +1-310-405-4475rrevelins@ Forward-Looking Statements Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies
Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies

Yahoo

timean hour ago

  • Yahoo

Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies

Boston, Massachusetts--(Newsfile Corp. - June 10, 2025) - Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of Elisabeth Gardiner, Ph.D., as Chief Scientific Officer. With more than 25 years of leadership in drug discovery and development across the biotech and pharmaceutical sectors, Dr. Gardiner brings deep translational expertise that will accelerate Tevard's mission to develop effective and durable tRNA-based therapies targeting the root cause of disease. As CSO, she will lead scientific strategy and R&D operations to expand Tevard's novel platform of engineered suppressor tRNAs, which recently demonstrated the first sustained restoration of full-length dystrophin in a Duchenne Muscular Dystrophy (DMD) model. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Dr. Gardiner's experience scaling discovery and translational programs will be critical as Tevard advances their lead program toward the clinic and expands their pipeline across additional indications. Tevard Biosciences is working to unlock the potential of tRNA-based therapies. The company's programs are based on its novel Suppressor tRNA technology platform that uses a viral vector to insert the normal amino acid at the site of the premature stop codon. Tevard's lead program targeting TTN-related dilated cardiomyopathy is advancing rapidly, with new data expected in the near future. Click image above to view full announcement. About Tevard Biosciences Tevard Biosciences is pioneering tRNA-based and other mRNA-modulating therapies to cure a broad range of genetic diseases. The privately held biotechnology company was founded by renowned scientists along with life science executives and entrepreneurs who are also fathers of children with rare diseases. Tevard is advancing the use of its novel suppressor tRNA platform in heart disease, muscular dystrophies, and neurological disorders. For more information, please visit Contacts: Michelle Linn michelle@ Source: Tevard To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CORRECTION FROM SOURCE: Bighorn Web Solutions Signs Magento Partnership with PSP Pharma to Drive E-Commerce Expansion
CORRECTION FROM SOURCE: Bighorn Web Solutions Signs Magento Partnership with PSP Pharma to Drive E-Commerce Expansion

Yahoo

timean hour ago

  • Yahoo

CORRECTION FROM SOURCE: Bighorn Web Solutions Signs Magento Partnership with PSP Pharma to Drive E-Commerce Expansion

This release corrects and replaces the press release issued by Bighorn Web Solutions on May 29, 2025 7:30 AM EDT. The updated version has been revised to reflect accurate information and ensure consistency across all referenced materials. Denver, Colorado--(Newsfile Corp. - June 10, 2025) - Bighorn Web Solutions, a leading enterprise-grade eCommerce agency, has signed a Magento eCommerce contract with PSP Pharma. Bighorn Web Solutions is responsible for the technical development of PSP Pharma's e-commerce systems, including and the PSP mobile application. The partnership is focused on improving platform performance, user experience, and operational efficiency to better serve PSP Pharma's growing customer base. CEO of Bighorn Web Solutions, Caleb Bradley, and Mamuka Bregvadze, administrative director of PSP Pharmacy To view an enhanced version of this graphic, please visit: PSP Pharma plans to expand its e-commerce platform across the region, with a focus on increasing access to health and self-care products in the Caucasus and Central Asia. This strategic move will enable the company to strengthen its presence and drive product sales throughout these markets. PSP has its eyes set on technology innovation and global growth. They're the first pharmaceutical company in Eastern Europe to fully implement Microsoft Dynamics 365 Business Central and LS Retail, setting a new benchmark for service quality, operational efficiency, and business process integration. The agreement with Bighorn Web Solutions positions PSP to lead the region in e-commerce excellence. "Partnering with PSP Pharma aligns strongly with Bighorn's global expertise and our commitment to empowering visionary companies. Signing this contract reinforces the mutual value we are creating and reflects our role as a trusted technology partner. As PSP expands into new regional markets, we are excited to deliver the solutions that support their growth and to play a key role in shaping the future of eCommerce in the pharmaceutical sector," said Caleb Bradley, CEO of Bighorn Web Solutions. To learn more about Bighorn Web Solutions and its enterprise eCommerce development services, please visit About Bighorn Web Solutions: Bighorn Web Solutions is a U.S.-based enterprise-grade e-commerce agency rooted in the Rocky Mountain region, comprised of senior-level engineers who are specialists, not generalists. With deep expertise in its respective niches, the agency understands the importance of staying ahead in an ever-evolving digital landscape. Media Contact: Caleb BradleyCEO, Bighorn Web To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store